person · Reporting owner
Windham-Bannister Susan Richards
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aridis Pharmaceuticals, Inc.ARDS · Entity 89417 | Director | June 27, 2024 | June 28, 2024 |
| CAMBRIDGE BANCORPCATC · Entity 88977 | Director | June 20, 2018 | June 21, 2018 |
| Histogen Inc.HSTO · Entity 112047 | Director | June 20, 2023 | June 21, 2023 |
| Humacyte, Inc.HUMA · Entity 6478 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aridis Pharmaceuticals, Inc.
Report date June 27, 2024 · Filed June 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2034-06-26 | Direct | 261,000 |
Reported balance
After 2024-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-27 · Grant · Acquired 200,000 · Balance 261,000 |
CAMBRIDGE BANCORP
Report date June 20, 2018 · Filed June 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 347 |
Reported balance
After 2018-06-20 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 347 · Balance 347 |
| Common StockSEC Table I · non-derivative | Direct | 735 |
Reported balance
Holding disclosure · report date 2018-06-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 735 |
Histogen Inc.
Report date June 20, 2023 · Filed June 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2033-06-20 | Direct | 6,835 |
Reported balance
After 2023-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-20 · Grant · Acquired 6,835 · Balance 6,835 F1: This option was issued to the Reporting Person, a non-employee director of the Issuer, for her service as a director of the Issuer. F2: The shares subject to this option become fully vested and exercisable on 6/20/2024, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was issued to the Reporting Person, a non-employee director of the Issuer, for her service as a director of the Issuer.
F2: The shares subject to this option become fully vested and exercisable on 6/20/2024, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Humacyte, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 · Expires 2036-06-11 | Direct | 80,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 80,000 · Balance 80,000 F1: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 22:01 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001104659-26-073620 · tm2617880-11_4seq1.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:31 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001818382-25-000114 · wk-form4_1750105909.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 20:36 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | GrantStock options · Derivative | 200,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001493152-24-025678 · ownership.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,000 Underlying: Common Stock · 200,000 shares Expires 2034-06-26 Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:12 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001818382-24-000142 · wk-form4_1718655168.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 16:05 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | GrantStock Options · Derivative | 15,000 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0001493152-23-033067 · ownership.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,500 Underlying: Common Stock · 15,000 shares Expires 2033-09-18 F1 · derivative.exercise_date: 50% of the options vest on the date of grant and 1,250 vest on a monthly basis thereafter for six months. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 16:11 UTC | Histogen Inc. HSTO · Entity 112047 | GrantStock Option (right to buy) · Derivative | 6,835 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001209191-23-038769 · doc4.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,835 Underlying: Common Stock · 6,835 shares Expires 2033-06-20 F1 · shares: This option was issued to the Reporting Person, a non-employee director of the Issuer, for her service as a director of the Issuer. F2 · derivative.exercise_date: The shares subject to this option become fully vested and exercisable on 6/20/2024, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001818382-23-000086 · wf-form4_168694619989218.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2033-06-15 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 15, 2024, after which 1/48 of the option will become exercisable on the 15th of each month through June 15, 2027. Read SEC document |
| June 05, 2023 Filed Jun 15, 2023 17:12 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-021478 · ownership.xml · derivative · entry 3 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: 5,000 shares of Common Stock vested on June 5, 2023 and 5,000 will vest on 12/5/2023. In the event that the Reporting Person's employment is terminated without cause by the Issuer, the RSUs will immediately vest. F3 · derivative.expiration_date: 5,000 shares of Common Stock vested on June 5, 2023 and 5,000 will vest on 12/5/2023. In the event that the Reporting Person's employment is terminated without cause by the Issuer, the RSUs will immediately vest. Read SEC document |
| June 05, 2023 Filed Jun 15, 2023 17:12 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-021478 · ownership.xml · nonDerivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 04, 2023 Filed Jun 15, 2023 17:12 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | GrantStock Options · Derivative | 15,000 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001493152-23-021478 · ownership.xml · derivative · entry 2 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,500 Underlying: Common Stock · 15,000 shares Expires 2033-05-04 F1 · derivative.exercise_date: 50% of the options vest on the three month anniversary of the date of grant and the remainder vest on the six month anniversary of the date of grant. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 08:57 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-034674 · ownership.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: 5,000 shares of Common Stock will vest on June 5, 2023 and 5,000 will vest on 12/5/2023. F2 · derivative.expiration_date: 5,000 shares of Common Stock will vest on June 5, 2023 and 5,000 will vest on 12/5/2023. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:22 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001818382-22-000092 · wf-form4_165515171376202.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2032-06-09 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 9, 2023, after which 1/48 of the option will become exercisable on the 9th of each month through June 9, 2026. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 16:41 UTC | Histogen Inc. HSTO · Entity 112047 | GrantStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-22-034098 · doc4.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2032-06-01 F1 · security: On June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 and the exercise price have been adjusted to reflect the Reverse Stock Split. F2 · shares: This option was issued to the Reporting Person, a non-employee director of the Issuer, for her service as a director of the Issuer. F3 · derivative.exercise_date: The shares subject to this option become fully vested and exercisable on 6/1/2023, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 19:29 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 13,000 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126700 · tm2130120-11_4seq1.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 19:01 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | GrantStock Options · Derivative | 8,500 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001104659-21-123305 · tm2129291-6_4seq1.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Common Stock · 8,500 shares Expires 2031-10-04 F1 · derivative.exercise_date: The stock options vest in equal installments over 12 months, beginning on October 4, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 16:18 UTC | Histogen Inc. HSTO · Entity 112047 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-21-020150 · doc4.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-03-10 F1 · derivative.exercise_date: The shares subject to the option shall vest in substantially equal installments on each of the first three anniversaries of the grant date, subject to reporting person's continued service as a director on such dates. Read SEC document |
| July 12, 2019 Filed Jul 15, 2019 08:06 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $10.01 | $0.00 |
DisclosureSEC source: 0001104659-19-040253 · a4.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-07-12 F1 · derivative.exercise_date: 972 of the stock options vested upon date of grant and the remaining stock options vest in equal installments over 35 months beginning on July 12, 2019. Read SEC document |
| July 12, 2019 Filed Aug 29, 2019 11:37 UTC Amendment | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $10.01 | $0.00 |
DisclosureSEC source: 0001104659-19-047878 · a4a.xml · derivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-07-12 F1 · derivative.exercise_date: The reporting person is filing this Amendment to correct the vesting terms for the stock options that were reported in the original form 4. The stock options vest in 36 equal monthly installments beginning on June 5, 2019. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 14:36 UTC | CAMBRIDGE BANCORP CATC · Entity 88977 | GrantCommon Stock | 347 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-18-000951 · primary_01.xml · nonDerivative · entry 1 Windham-Bannister Susan Richards · CIK 0001713760 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.